BACKGROUND: Using transrectal saturation prostate biopsy (SPBx) as an initial strategy remains a controversial topic.
OBJECTIVE: To compare SPBx with extended prostate biopsy (EPBx) as an initial biopsy template in a large sequential cohort study.
DESIGN, SETTING, AND PARTICIPANTS: We reviewed 438 men with initial SPBx and 3338 men who underwent initial EPBx between January 2002 and October 2011.
INTERVENTION: Office-based SPBx under periprostatic local anesthesia.
OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The yield of SPBx was compared with EPBx. Multivariable logistic regression models addressed cancer detection (CD) and cancer characteristics.
RESULTS AND LIMITATIONS: Overall CD was 51.6% and 42.6% in men who underwent initial SPBx and EPBx, respectively. Multivariate analysis confirmed that SPBx was an independent predictor factor correlated with the CD (odds ratio [OR]: 1.66; 95% confidence interval [CI], 1.30-1.92). Stratified by prostate-specific antigen (PSA) values, CD was higher in SPBx compared with EPBx, 47.1% versus 32.8% (OR: 2.00; 95% CI, 1.19-3.38) in patients with a PSA < 4 ng/ml and 50.9% versus 42.9% in patients with a PSA from 4 ng/ml to 9.9 ng/ml (OR: 1.62; 95% CI, 1.20-2.20). By contrast, SPBx did not increase CD in men with a PSA >10 ng/ml (60.0% vs 61%; OR: 1.42; 95% CI, 0.70-2.89). There was no significant difference in the detection of insignificant cancer (p = 0.223) or low-risk cancer (p = 0.077) between the two biopsy schemes. The limitation of our study is its retrospective nature and inhomogeneity.
CONCLUSIONS: Compared with EPBx, SPBx significantly increases CD as an initial biopsy strategy in men with a PSA < 10 ng/ml without a significant increase in the detection of insignificant cancer. These findings suggest that SPBx may merit further investigation as an initial biopsy strategy in men with a PSA < 10 ng/ml in hopes of avoiding repeat biopsy for missed malignancy during the initial biopsy.
Written by:
Li YH, Elshafei A, Li J, Gong M, Susan L, Fareed K, Jones JS. Are you the author?
Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Urology, Cancer Center, Sun Yat-Sen University, Guangzhou, People's Republic of China.
Reference: Eur Urol. 2013 Jun 4. pii: S0302-2838(13)00556-3.
doi: 10.1016/j.eururo.2013.05.047
PubMed Abstract
PMID: 23768632
UroToday.com Prostate Cancer Section
